VANGUARD PLUS 5 L4

Indications

• Acute respiratory infection
• Conjunctivitis
• Gastroenteritis
• Cystitis
• Meningitis
• Pneumonia

Dosage

Children: There is no specific dosage as adenovirus infections are generally self-limiting. Symptomatic treatment is advised.

Adults: There is no specific dosage as adenovirus infections are typically self-limiting. Supportive care is recommended.

Mechanism of action

Adenoviruses infect host cells through interactions with specific receptors on the cell surface, facilitating virus entry and subsequent release of viral DNA into the host cell nucleus. The viral DNA then utilizes the host cell's machinery to replicate and produce new viral particles, eventually leading to cell lysis and the release of new virions.

Pharmacodynamics

The clinical manifestations of adenovirus infections can range widely depending on the serotype and host factors. The immune response plays a critical role in controlling the infection, with both innate and adaptive immunity contributing to viral clearance. In general, adenovirus infections stimulate a robust immune response, which may cause symptoms such as fever, sore throat, and conjunctivitis.

Pharmacokinetics

Adenoviruses are typically transmitted via respiratory droplets or direct contact with contaminated surfaces. After exposure, the viruses can replicate in the epithelial cells of the respiratory tract, conjunctiva, or gastrointestinal tract. The viral shedding can occur for several days to weeks, depending on the individual's immune response. Adenoviruses do not have a specific treatment, and management focuses on symptomatic relief and supportive care.

Adverse effects

• Fever
• Sore throat
• Cough
• Conjunctivitis
• Diarrhea
• Pneumonia
• Bronchitis
• Sinusitis

Precautions

• In immunocompromised patients, adenovirus can cause severe disease.
• Caution should be exercised in individuals with underlying respiratory conditions.

Pregnancy

Adenovirus infections can occur during pregnancy, but specific risks to the fetus are not well established. Consultation with healthcare providers is advised.

Breast-feeding

Adenovirus can be transmitted through breast milk; however, the clinical significance is not clear. Breastfeeding mothers should consult healthcare professionals if they are infected.

Storage

Adenoviruses are laboratory-based entities and are typically stored in controlled environments within laboratory settings, rather than as commercially available drugs.

Indications

• Leptospirosis
• Renal impairment due to leptospirosis
• Hepatic complications associated with leptospirosis

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidance, as no specific dosing is provided.

Adults: Refer to specific guidelines for antibiotic therapy based on the severity and stage of leptospirosis, as no specific dosing is provided.

Mechanism of action

Leptospira canicola, like other leptospires, invades host tissues and elicits an immune response. The bacteria can penetrate mucosal membranes and survive in the renal tubules, leading to inflammation and damage. The immune response involves both humoral and cell-mediated immunity, which can contribute to the clinical manifestations of the disease, including vasculitis and organ dysfunction.

Pharmacodynamics

The pharmacodynamics of treatment for leptospirosis focuses on the elimination of the organism and the resolution of symptoms. Antibiotics, such as doxycycline and penicillin, act by inhibiting bacterial cell wall synthesis or protein synthesis, leading to cell lysis and death. The effectiveness of these treatments is influenced by the timing of administration, as early treatment can prevent severe complications.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat leptospirosis, such as doxycycline, include rapid absorption from the gastrointestinal tract, high bioavailability, and extensive tissue distribution. Doxycycline, for example, is metabolized by the liver and excreted primarily in the urine. The half-life of doxycycline allows for once or twice daily dosing, making it convenient for treatment regimens.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether canicola is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Pain management
• Inflammation
• Infections
• Chronic diseases
• Allergic reactions

Dosage

Children: Dosage for paediatric canines (puppies) also varies widely depending on the specific medication, age, and weight of the puppy. Veterinary guidance is crucial for determining appropriate doses.

Adults: Dosage for adult canines varies based on the specific medication and condition being treated. It is essential to consult veterinary guidelines or a veterinarian for appropriate dosing.

Mechanism of action

The mechanism of action of canine medications varies widely depending on the specific drug class. For example, non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase enzymes (COX-1 and COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Antibiotics may work by inhibiting bacterial cell wall synthesis or protein synthesis, while corticosteroids reduce inflammation by inhibiting immune response.

Pharmacodynamics

Pharmacodynamics in canines involves understanding how drugs affect the body, including their therapeutic effects and potential side effects. For example, NSAIDs provide analgesic and anti-inflammatory effects, while antibiotics target specific pathogens to eliminate infections. The response to drugs can vary based on factors such as breed, age, and overall health status.

Pharmacokinetics

Pharmacokinetics in canine patients encompasses the absorption, distribution, metabolism, and excretion of drugs. Canine physiology can influence these processes; for example, drugs may be absorbed more quickly in dogs due to differences in gastrointestinal pH and transit time. Metabolism often occurs in the liver, with variations based on breed and age affecting drug clearance. Excretion primarily takes place through the kidneys.

Pregnancy

Safety during pregnancy has not been established. Consult a veterinarian for guidance.

Breast-feeding

Safety during lactation has not been established. Consult a veterinarian for guidance.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Prevention of canine distemper through vaccination
• Supportive treatment for infected dogs

Dosage

Children: No specific dosage available, refer to guidelines for vaccination schedules.

Adults: No specific dosage available, refer to guidelines for vaccination schedules.

Mechanism of action

Canine distemper virus primarily infects and replicates in lymphoid tissue, leading to immune suppression, and subsequently affects epithelial tissues in the respiratory, gastrointestinal, and nervous systems. The virus enters host cells via the signaling lymphocytic activation molecule (SLAM) receptor, which is expressed on immune cells, facilitating its spread throughout the body.

Pharmacodynamics

The immune response to CDV involves both humoral and cellular immunity. Vaccination induces an immune response that generates neutralizing antibodies, which prevent viral entry into host cells. Infected animals may develop severe immunosuppression, making them susceptible to secondary infections. The clinical manifestations depend on the severity of the infection and the host's immune response.

Pharmacokinetics

The pharmacokinetics of canine distemper virus are not typically described in terms of absorption, distribution, metabolism, and excretion like conventional drugs. Instead, the focus is on viral replication and the host immune response. The incubation period for distemper can vary but generally ranges from 1 to 2 weeks. The duration of the immune response post-vaccination can last for several years, depending on the type of vaccine used.

Pregnancy

No specific data available on the effects of distemper treatment in pregnant individuals, consult relevant guidelines.

Breast-feeding

No specific data available on the effects of distemper treatment during breastfeeding, consult relevant guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Clinical term 1
• Common term 1
• Clinical term 2
• Common term 2

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Dose acts by modulating the activity of specific neurotransmitter receptors and ion channels, influencing various physiological pathways. Its precise mechanism may involve interactions with G-protein coupled receptors, leading to downstream signaling effects that impact cellular responses.

Pharmacodynamics

Dose exhibits a range of effects depending on the dosage and target tissues. It is known to alter neurotransmitter release, affect ion conductance, and influence metabolic pathways, thereby contributing to its therapeutic efficacy and potential side effects.

Pharmacokinetics

Dose is generally absorbed following administration, with peak plasma concentrations occurring within a specified timeframe. Its distribution is influenced by tissue binding and permeability across cell membranes. The drug is metabolized primarily in the liver, with metabolites being excreted via renal and biliary routes. The half-life can vary based on individual patient factors, including age, liver function, and other concurrent medications.

Indications

• Gastroenteritis caused by Salmonella enterica serotype Grippotyphosa
• Systemic infections in immunocompromised patients
• Foodborne illness outbreaks

Dosage

Children: Refer to clinical guidelines for appropriate antibiotic therapy based on susceptibility testing.

Adults: Refer to clinical guidelines for appropriate antibiotic therapy based on susceptibility testing.

Mechanism of action

Grippotyphosa invades the intestinal epithelium, evading the host's immune response. It utilizes a type III secretion system to inject virulence factors into host cells, promoting bacterial entry and survival within macrophages, which leads to systemic infection.

Pharmacodynamics

The pathogenicity of Grippotyphosa is characterized by its ability to induce inflammation and disrupt the intestinal barrier. The bacteria can replicate within macrophages, leading to prolonged immune response and potential dissemination into the bloodstream, causing systemic illness. Antibiotic susceptibility may vary, necessitating sensitivity testing.

Pharmacokinetics

As a bacterial pathogen, Grippotyphosa is not a drug with pharmacokinetic properties. However, when treated with antibiotics, the pharmacokinetics of the chosen antibiotic will dictate its effectiveness against the bacteria. Typically, antibiotics are absorbed, distributed, metabolized, and excreted in a way that targets the infection site effectively.

Pregnancy

Consult a healthcare professional before use. Data on safety in pregnancy is limited.

Breast-feeding

Consult a healthcare professional before use. Limited data on excretion in breast milk.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Leptospirosis
• Icterhaemorrhagiae infection
• Severe bacterial infections
• Acute febrile illness

Dosage

Children: Paediatric dosing for leptospirosis requires careful consideration of the child's weight and age, and should be guided by current clinical guidelines and expert recommendations.

Adults: Antibiotic treatment involves specific dosing based on the chosen agent, often guided by renal function and severity of the disease. Refer to specific guidelines for appropriate antibiotic choice and dosing.

Mechanism of action

Leptospirosis is primarily caused by Leptospira bacteria, which invade host tissues and evade the immune response. The bacteria can enter the bloodstream, leading to systemic infection. They produce various virulence factors that impair host immune response, allowing for persistent infection and tissue damage.

Pharmacodynamics

The pharmacodynamics of treatments for leptospirosis, such as antibiotics, involve the inhibition of bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, which ultimately leads to bacterial cell death. The effectiveness of treatment is influenced by the stage of the disease and the severity of the infection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat leptospirosis vary by drug. Generally, these drugs are absorbed from the gastrointestinal tract, distributed throughout body tissues, and excreted mainly via the kidneys. The half-life and clearance rates depend upon the specific antibiotic used and the patient's renal function.

Pregnancy

The safety of icterohaemorrhagiae during pregnancy has not been established. Caution is advised.

Breast-feeding

It is not known if icterohaemorrhagiae is excreted in human milk. Caution is recommended.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Leptospirosis
• Acute febrile illness
• Renal failure due to leptospirosis
• Severe liver dysfunction
• Hemorrhagic manifestations

Dosage

Adults: Refer to the BNF for appropriate antibiotic treatment regimens based on clinical severity and patient factors

Mechanism of action

Leptospira bacteria invade host tissues and can evade the immune response, leading to systemic infection. They are known to bind to host cells through specific receptors, facilitating their entry and subsequent multiplication. The immune response to the infection may result in an inflammatory response, contributing to tissue damage and the clinical manifestations of leptospirosis.

Pharmacodynamics

The pathophysiology of leptospirosis involves both the virulence factors of Leptospira and the host's immune response. The bacteria can induce a strong inflammatory response, leading to vasculitis and tissue damage. Organ dysfunction may occur due to the direct effects of the bacteria and the resultant immune-mediated injury. The severity of the disease can vary greatly depending on the serovar of Leptospira involved and the host's immune status.

Pharmacokinetics

Leptospira has no direct pharmacokinetics as it is a bacterium rather than a drug. However, the treatment of leptospirosis typically involves antibiotics. Common antibiotics used include doxycycline, penicillin, and ceftriaxone. The pharmacokinetics of these antibiotics vary; for example, doxycycline is well-absorbed orally and has a long half-life, allowing for once or twice daily dosing, while penicillin has a shorter half-life and requires more frequent dosing. The clearance of these drugs is influenced by renal function, which may be compromised in patients with severe leptospirosis.

Adverse effects

• Fever
• Headache
• Muscle pain
• Nausea
• Vomiting
• Jaundice
• Rash
• Meningitis
• Pulmonary hemorrhage
• Acute kidney injury

Precautions

• Monitor renal function in patients with existing kidney issues
• Use caution in immunocompromised patients
• Assess liver function prior to treatment

Pregnancy

The safety of leptospira treatment during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Not well studied in breastfeeding women. Caution is advised.

Storage

Store at room temperature, away from direct sunlight. Keep out of reach of children.

Indications

• Measles
• Mumps
• Rubella
• Varicella (chickenpox)
• Yellow fever
• Rotavirus
• Intranasal influenza

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and vaccine type.

Adults: Refer to specific product guidelines for dosing information, as it can vary by vaccine type and brand.

Mechanism of action

Live vaccines work by introducing a weakened or attenuated form of a pathogen into the body. This stimulates the immune system to recognize and respond to the pathogen, leading to the production of antibodies and memory cells that provide long-term protection against future infections by the same pathogen.

Pharmacodynamics

The pharmacodynamics of live vaccines involve the activation of both humoral and cellular immunity. Following vaccination, the immune system generates a robust response, including the production of specific antibodies and the activation of T cells that can recognize and eliminate infected cells. This dual action helps establish long-term immunity.

Pharmacokinetics

The pharmacokinetics of live vaccines vary depending on the specific vaccine. Generally, the vaccine is administered via injection, allowing the live attenuated organisms to enter the bloodstream. The immune response typically begins within days and can last for years, depending on the vaccine. Live vaccines are usually stored under refrigeration to maintain their viability, and they should be administered within their expiration dates.

Interactions

• livevaccines + abrocitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + baricitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + filgotinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + dexrazoxane: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + iron chelators: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ponesimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + upadacitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + diroximelfumarate: Moderate (increases risk of generalised infection (possibly life-threatening))

Dosage

Children: Refer to specific product guidelines or consult a healthcare professional for dosing information.

Adults: Refer to specific product guidelines or consult a healthcare professional for dosing information.

Pregnancy

There is insufficient data to determine the safety of Manhattan during pregnancy. Use only if the benefits outweigh the risks.

Breast-feeding

It is unknown whether Manhattan is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Dosage

Children: Paediatric dosing for modified drugs must be derived from established guidelines or clinical recommendations. Consult the relevant guidelines or formulary for age-appropriate dosing.

Adults: Dosing for modified drugs is highly specific to each agent and should be determined based on clinical guidelines and individual patient needs. It is essential to refer to specific product literature or a professional drug reference for accurate dosing information.

Mechanism of action

The mechanism of action for modified drugs varies significantly depending on their specific structure and target. Generally, modifications can enhance binding affinity to receptors, alter metabolic pathways, or improve cellular uptake. For example, modifications may lead to increased selectivity for target enzymes or receptors, thereby improving therapeutic outcomes and reducing off-target effects.

Pharmacodynamics

Pharmacodynamics of modified drugs typically includes alterations in the drug's potency and efficacy, influenced by the structural changes made. These modifications can lead to improved therapeutic indices by enhancing the desired pharmacological effect while minimizing adverse effects. Such changes may also affect receptor activation, signal transduction pathways, and downstream physiological effects.

Pharmacokinetics

The pharmacokinetics of modified drugs can be significantly altered based on the nature of the modifications. Factors such as absorption, distribution, metabolism, and excretion (ADME) can be optimized to improve bioavailability and half-life. For instance, modifications might enhance solubility, stability, or resistance to enzymatic degradation, affecting how the drug is processed in the body.

Indications

• Hypertension
• Angina pectoris
• Migraine prophylaxis
• Tachyarrhythmias
• Heart failure

Dosage

Children: Refer to the BNF for Children for pediatric dosing recommendations, as these will depend on the specific indication and the patient's age and weight.

Adults: Refer to the BNF for specific dosing guidelines, as it may vary based on the condition being treated and individual patient factors.

Mechanism of action

Nadolol exerts its effects by blocking beta-1 and beta-2 adrenergic receptors in the heart and peripheral vasculature. By antagonizing these receptors, nadolol decreases heart rate, myocardial contractility, and conduction velocity through the atrioventricular node, which reduces cardiac workload and oxygen consumption. Additionally, blockade of beta-2 receptors can lead to peripheral vasoconstriction, but this effect is generally outweighed by the overall reduction in heart activity.

Pharmacodynamics

Nadolol reduces heart rate and myocardial oxygen demand by inhibiting the actions of catecholamines on the heart. The drug also has a long half-life, allowing for once-daily dosing. The antihypertensive effects are due to decreased cardiac output and a reduction in renin release from the kidneys, which leads to lower levels of angiotensin II and subsequently vasodilation.

Pharmacokinetics

Nadolol is well absorbed following oral administration, with peak plasma concentrations occurring within 1 to 4 hours. It has a long elimination half-life of approximately 20 to 24 hours, allowing for once-daily dosing. Nadolol is primarily excreted unchanged in the urine, with minimal hepatic metabolism, making it suitable for use in patients with liver dysfunction. The drug's pharmacokinetic profile can be affected by renal impairment, necessitating careful monitoring and potential dose adjustments.

Pregnancy

There are no well-controlled studies of nadl in pregnant women. Its use should be considered only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether nadl is excreted in human milk. Caution should be exercised when administering to a nursing woman.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Indications

• Croup (laryngotracheobronchitis)
• Bronchiolitis
• Pneumonia
• Upper respiratory tract infections

Mechanism of action

Parainfluenza viruses enter host cells and replicate by binding to specific receptors on the cell surface, mainly through the hemagglutinin-neuraminidase (HN) and fusion (F) proteins. Once inside the cell, the viral RNA is released and hijacks the host's cellular machinery to produce viral proteins and replicate the viral genome, leading to the assembly of new virions. This process ultimately results in cell lysis and the release of new viral particles, facilitating the spread of infection.

Pharmacodynamics

The immune response to parainfluenza infection involves both innate and adaptive mechanisms. The initial response includes the release of cytokines and activation of immune cells, such as macrophages and T cells. This immune response aims to control viral replication and clear the virus from the respiratory tract. Symptoms associated with parainfluenza infections, such as cough and difficulty breathing, are often a result of inflammation and airway obstruction due to the immune response.

Pharmacokinetics

As a virus, parainfluenza does not have pharmacokinetics in the traditional sense applied to drugs; however, the viral replication cycle is crucial for understanding its behavior in the human body. Following exposure, the incubation period typically ranges from 2 to 7 days. The virus can be shed from the respiratory tract for several days, with peak shedding occurring at the onset of symptoms. The immune system gradually controls the infection, leading to the resolution of symptoms.

Adverse effects

• Fever
• Rhinorrhea
• Cough
• Sore throat
• Wheezing
• Shortness of breath
• Lethargy
• Croup
• Pneumonia

Precautions

• Monitor respiratory status in patients with underlying respiratory conditions
• Use caution in immunocompromised patients

Pregnancy

There are no known specific risks to pregnant women, but caution is advised.

Breast-feeding

Generally considered safe, but consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Fifth disease (erythema infectiosum)
• Aplastic crisis in patients with hemolytic anemia
• Parvovirus B19 infection in immunocompromised patients

Dosage

Children: There are no specific pharmacological treatments for parvovirus infections; management is supportive. In children, parvovirus B19 infection typically resolves on its own, and symptomatic treatment is

Adults: There are no specific pharmacological treatments for parvovirus infections; management is supportive. Adults with parvovirus B19 infection are generally advised to rest and manage symptoms such as fever and pain.

Mechanism of action

Parvovirus B19 infects erythroid progenitor cells in the bone marrow, leading to lysis of these cells and a subsequent decrease in red blood cell production. The virus attaches to its receptor, globoside (also known as P antigen), which is present on the surface of erythroid progenitor cells. This binding facilitates viral entry and replication, disrupting normal erythropoiesis.

Pharmacodynamics

Parvovirus B19's primary effect is on the hematopoietic system, particularly impacting the production of red blood cells. In immunocompetent individuals, infection typically results in mild symptoms and self-limiting disease. However, in individuals with compromised immune systems or underlying hematological conditions, the virus can lead to severe anemia and other complications due to its effect on erythroid progenitors.

Pharmacokinetics

Parvovirus does not follow traditional pharmacokinetic principles as it is a virus rather than a pharmaceutical agent. Its replication occurs intracellularly, and it is spread via respiratory droplets or blood. The incubation period ranges from 4 to 14 days, and viremia can persist for weeks. The immune response is crucial for clearing the virus, with specific antibodies developing within a few weeks of infection.

Adverse effects

• Fever
• Malaise
• Rash
• Joint pain
• Anemia
• Lethargy

Precautions

• Immunocompromised patients may experience more severe symptoms.
• Pregnant women should be cautious due to potential risks to the fetus.

Pregnancy

Parvovirus B19 infection during pregnancy can lead to serious complications, including fetal anemia and hydrops fetalis.

Breast-feeding

There is no evidence to suggest that parvovirus B19 is transmitted through breast milk.

Storage

Parvovirus is a virus and does not require storage in a conventional sense; however, specimens should be handled according to biosafety guidelines.

Dosage

Children: Refer to official prescribing information or clinical guidelines for appropriate paediatric dosing.

Adults: Refer to official prescribing information or clinical guidelines for appropriate adult dosing.

Pregnancy

Data on the use of pomona during pregnancy is limited. It is recommended to assess the risk versus benefit before administration to pregnant patients.

Breast-feeding

The safety of pomona during breastfeeding is not established. Caution is advised, and it is recommended to consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.